Meng, J., Lister, J., Vataire, A., Casciano, R., & Dinet, J. (2018). Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England. Clinicoecon Outcomes Res.

Meng, Jie, Johanna Lister, Anne-Lise Vataire, Roman Casciano, và Jerome Dinet. "Cost-effectiveness Comparison of Cabozantinib With Everolimus, Axitinib, and Nivolumab in the Treatment of Advanced Renal Cell Carcinoma Following the Failure of Prior Therapy in England." Clinicoecon Outcomes Res 2018.

Meng, Jie, et al. "Cost-effectiveness Comparison of Cabozantinib With Everolimus, Axitinib, and Nivolumab in the Treatment of Advanced Renal Cell Carcinoma Following the Failure of Prior Therapy in England." Clinicoecon Outcomes Res 2018.